CCM Pharma offers 525bp-550bp on euro TLB
CCM Pharma, the new pharmaceutical company that private equity group Cinven is forming by merging two of its recent acquisitions, has set price talk on its new £160m-equivalent euro-denominated term loan ‘B’ at 525bp-550bp.
The loan is part of £388.6m of debt that Cinven is raising to merge its latest acquisition, Amdipharm, with its September purchase, Mercury Pharma. The new debt is effectively an add-on to the £235m of senior loans that Cinven used to acquire Mercury Pharma.
Bankers at the bookrunners
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: email@example.com or find out more online here.